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The ability to utilize formalin-fixed, paraffin-embedded (FFPE) archival specimens reliably for high-resolution molecular genetic analysis
would be of immense practical application in the study of human disease. We have evaluated the ability of the GenomePlex whole genome
amplification (WGA) kit to amplify frozen and FFPE tissue for use in array CGH (aCGH). GenomePlex gave highly representative data compared
with unamplified controls both from frozen material (Pearson’s R2 = 0.898) and from FFPE (R2 = 0.883). Artifactual amplification observed using
DOP-PCR at chromosomes 1p, 3, 13q, and 16p was not seen with GenomePlex. Highly reproducible aCGH profiles were obtained using as little
as 5 ng starting material from FFPE (R2 = 0.918). This WGA method should readily lend itself to the determination of DNA copy number
alterations from small fresh-frozen and FFPE clinical tumor specimens, although some care must be taken to optimize the DNA extraction
procedure.
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ular genetic techniques to the study of human disease has made
immense contributions to the identification of genes and
pathways associated with disease etiology and progression. In
particular, the genomic analysis of tumor DNA has identified
alterations in sequence and copy number associated with the
diagnosis, prognosis, and treatment response in a variety of
cancer types [1,2]. For the most part, these studies have
necessarily focused on samples flash frozen at surgery, to
provide the highest quality nucleic acid for analysis. The
development of methodologies to allow the routine analysis of
archival pathology specimens, usually fixed in formalin and
embedded in paraffin (FFPE) and potentially stored for many
years, would be of immense benefit for translational research.
Additionally, the use of FFPE material allows precision
laser-based microdissection strategies facilitating detailed0888-7543/$ - see front matter D 2005 Elsevier Inc. All rights reserved.
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1 These authors contributed equally to this work.molecular analysis on minute, e.g., preinvasive lesions or
specific cellular compartments, free from contamination of
surrounding tissue. These small foci of cells require a robust,
unbiased system of whole genome amplification (WGA),
which is tolerant of the often poor-quality, highly degraded
DNA present in FFPE material.
One of the most useful and widely used techniques for the
genome-wide assessment of DNA copy number alterations is
comparative genomic hybridization (CGH). Since its inception
in 1992, based on hybridization to metaphase chromosomes
[3], it has been widely used to characterize the molecular
genetic aspects of a range of human diseases and has been
successfully applied to FFPE material [4–9]. The most
common method of WGA for CGH analysis of FFPE material
has been degenerate oligonucleotide (DOP)-PCR, which uses a
degenerate universal primer and low annealing temperature to
generate amplified material from across the entire genome [10].
With the advent of microarray-based CGH [11,12], the
resolution of copy number change detection has increased
immensely and is limited only by the size and spacing of the6) 298 – 306
www.el
Table 1
Quantitation of amplified DNA from frozen and FFPE samples by DOP-PCR
and GenomePlex
DOP-PCR GenomePlex
5 ng 10 ng 50 ng 5 ng 10 ng 50 ng
Frozen 1545 ng
(309-fold)
2460 ng
(246-fold)
5685 ng
(114-fold)
2952 ng
(590-fold)
3138 ng
(314-fold)
5534 ng
(111-fold)
FFPE 1342 ng
(269-fold)
1305 ng
(131-fold)
2478 ng
(50-fold)
631 ng
(126-fold)
568 ng
(57-fold)
1209 ng
(24-fold)
Average quantities of amplification product are given for each input DNA
concentration, along with the fold amplification for each.
S.E. Little et al. / Genomics 87 (2006) 298–306 299features of the arrays. In this context, there are concerns about
the fidelity and reproducibility of techniques such as DOP-
PCR, which have long been reported to show amplification
biases [13]. At the metaphase resolution, these have been
accepted, either by careful control of hybridization experiments
or by the use of dynamic standard reference intervals [14,15],
or else by ignoring chromosomal loci thought to be inaccu-
rately represented, such as chromosomes 1p, 16p, and 19. At
the array CGH (aCGH) level, such biases may be more
pronounced and the limitations less acceptable.
We have evaluated the ability of the GenomePlex WGA Kit
developed by Rubicon Genomics to amplify frozen and FFPE
tissue for use in aCGH. GenomePlex WGAworks by randomly
digesting the DNA template into a fragmented library of DNA
molecules, making it potentially well suited to the fragmented
template DNA associated with FFPE material. GenomePlex
WGA converts fragmented DNA to PCR-amplifiable mole-
cules flanked by universal priming sites, which are then
amplified by standard PCR, resulting in whole genome
amplification. This technique was compared to standard
DOP-PCR on microarrays consisting of 5623 BAC clones
corresponding to an approximate 0.9-Mb spacing across the
genome. We have analyzed paired frozen/FFPE samples and
have assessed the fidelity of aCGH data generated with both
amplification techniques. We demonstrated the efficacy of the
GenomePlex approach and the improvement on WGA fidelity
compared with DOP-PCR. We also report the successful
WGA-aCGH analysis of FFPE material using GenomePlex
with as little as 5 ng starting template DNA.
Results
Amplification by DOP-PCR and GenomePlex
DOP-PCR products consisted of fragments of up to 1 kb in
FFPE samples (up to 2 kb in frozen samples), while the
GenomePlex fragments tended to be <800 bp (Fig. 1).
Increased amounts of starting DNA template did not appear
to result in longer length fragments after amplification.
Efficiency of amplification was found to be critically depen-Fig. 1. GenomePlex whole genome amplification of FFPE DNA. 0.8% agarose
gels depicting products of GenomePlex amplification of 10 representative
FFPE Wilms tumor specimens (lanes 2–11). Lane 1, 1 kb ladder.dent on the DNA extraction procedure used. Varying the
protocol for extraction of genomic DNA from FFPE sections,
although giving similar amounts of DNA quantitation by both
spectrophotometry (A260) and fluorescence (PicoGreen), failed
to give consistent WGA across a range of samples, particularly
with GenomePlex reactions (data not shown). Even with an
optimized DNA extraction protocol, DOP-PCR gave more
consistently reproducible amplification across a greater number
of FFPE samples from different sources (approx 85% of cases),
with GenomePlex generating amplification product in approx-
imately 58% of cases.
When successful, both DOP-PCR and GenomePlex WGA
were able to generate microgram quantities of DNA from
nanograms of both frozen and FFPE template DNA, with
frozen template giving better yields than FFPE (Table 1).
GenomePlex generated more product from frozen DNA than
did DOP-PCR, although not from FFPE. There was an
inversely proportional relationship between yield and fold
amplification dependent on input DNA quantity, with an
optimum input quantity for GenomePlex of approximately 5
ng. WGA using GenomePlex could be achieved from as little
as 100 pg of starting material (data not shown), although this
was not consistent.
Reproducibility of WGA by aCGH
The reproducibility of aCGH experiments using different
WGA techniques was assessed by replicate cohybridizations of
different amplifications using the same starting template DNA.
Table 2 demonstrates the Pearson correlation coefficient for
averaged DOP-PCR:DOP-PCR and GenomePlex:GenomePlex
experiments for all clones, as well as individual chromosomes,
using both frozen and FFPE samples. Unamplified:unamplified
experiments are also provided to give an indication of aCGH
experimental variation in our system.
The overall experimental variation was slightly higher for
aCGH profiles generated with unamplified FFPE samples
(Pearson’s correlation = 0.887) compared with those of
unamplified frozen tumors (0.935), although this was not
statistically significant. The reproducibility of independent
replicate GenomePlex amplifications as assessed by aCGH
was equivalent to unamplified control experiments (Pearson’s
R2 = 0.937 for frozen samples; 0.854 for FFPE) and
represented no statistical difference between the two. DOP-
PCR, however, performed considerably less reliably, with
Table 2
Correlations between replicate experiments as measured by aCGH
Chromosome Frozen FFPE
Unamplified GenomePlex DOP-PCR Unamplified GenomePlex DOP-PCR
All 0.9354 0.9371 0.8583 0.8868 0.8536 0.6821
1 0.9318 0.9332 0.8491 0.9135 0.8861 0.7495
2 0.9438 0.9534 0.8677 0.9393 0.9153 0.7449
3 0.9185 0.9302 0.8201 0.9058 0.7990 0.6677
4 0.9401 0.9299 0.8301 0.9108 0.8553 0.7329
5 0.9087 0.9248 0.8401 0.8992 0.8832 0.6744
6 0.9494 0.9485 0.8732 0.9421 0.9094 0.6285
7 0.8860 0.9107 0.8790 0.8805 0.8660 0.7120
8 0.9444 0.9360 0.8563 0.8753 0.8841 0.7320
9 0.9275 0.9230 0.8950 0.8580 0.8366 0.7690
10 0.8484 0.9068 0.8501 0.8510 0.8958 0.7188
11 0.9314 0.9237 0.8518 0.8553 0.8111 0.7381
12 0.9253 0.9198 0.8134 0.8704 0.8888 0.7825
13 0.8909 0.9125 0.8130 0.7945 0.8128 0.6670
14 0.9263 0.9304 0.7850 0.8431 0.8013 0.6947
15 0.9317 0.9169 0.8629 0.8828 0.8936 0.7760
16 0.9309 0.9092 0.8681 0.8578 0.8236 0.6937
17 0.9493 0.9370 0.9015 0.9111 0.8997 0.7471
18 0.9086 0.9294 0.7751 0.8988 0.8513 0.6753
19 0.8580 0.8747 0.8327 0.8340 0.7749 0.5715
20 0.9265 0.7566 0.8389 0.7471 0.7142 0.6215
21 0.8813 0.9099 0.8783 0.9062 0.8260 0.7759
22 0.2293 0.7181 0.6826 0.7405 0.8134 0.7071
X 0.9350 0.9316 0.8479 0.8050 0.6774 0.3232
Y 0.9352 0.9182 0.8901 0.8132 0.3218 0.2175
Pearson’s correlation coefficients are given for all BAC clones on the array, as well as being subdivided by chromosome.
Table 3
Correlations between amplified and unamplified frozen and FFPE samples as
measured by aCGH
Chromosome Frz
GenomePlex
Frz
DOP
Frz
Unamp
FFPE
GenomePlex
FFPE
DOP
Frz
Unamp
Frz
Unamp
FFPE
Unamp
FFPE
Unamp
FFPE
Unamp
All 0.8977 0.7396 0.8423 0.8833 0.5163
1 0.8847 0.7419 0.8376 0.8771 0.5831
2 0.9031 0.7360 0.8691 0.9899 0.5154
3 0.8572 0.7218 0.7549 0.8426 0.3727
4 0.8773 0.6347 0.8514 0.8303 0.4798
5 0.8843 0.6084 0.8923 0.8592 0.5793
6 0.9424 0.8103 0.9499 0.9422 0.5764
7 0.8616 0.6569 0.8048 0.8731 0.5301
8 0.9290 0.7328 0.9029 0.9054 0.5298
9 0.9023 0.7967 0.8344 0.9167 0.7027
10 0.8644 0.6934 0.7713 0.8581 0.4333
11 0.8829 0.7244 0.7633 0.8204 0.5454
12 0.8132 0.6936 0.7468 0.8239 0.5441
13 0.8776 0.7452 0.7192 0.7709 0.3264
14 0.8742 0.7516 0.7529 0.8419 0.4946
15 0.8399 0.7060 0.7599 0.8158 0.4712
16 0.9249 0.8278 0.8365 0.8652 0.5366
17 0.8911 0.4454 0.8950 0.8622 0.5152
18 0.8979 0.7406 0.7815 0.8442 0.4816
19 0.7805 0.7897 0.7862 0.7746 0.5684
20 0.7311 0.6873 0.7514 0.6347 0.6270
21 0.8833 0.7186 0.8487 0.8253 0.5787
22 0.8618 0.7830 0.5710 0.8308 0.2428
X 0.8839 0.6683 0.8499 0.8486 0.3627
Y 0.9394 0.8745 0.9319 0.8665 0.3017
Pearson’s correlation coefficients are given for all BAC clones on the array, as
well as being subdivided by chromosome.
S.E. Little et al. / Genomics 87 (2006) 298–306300Pearson’s correlations of 0.858 from frozen and 0.682 from
FFPE. These were significantly less reproducible than the
control unamplified experiments for both frozen ( p = 0.018, t
test) and FFPE ( p < 0.001, t test).
Fidelity of WGA
Next we sought to determine the correlation between
amplified and unamplified template DNA from both frozen
and FFPE samples by analyzing matched pairs of samples from
the same tumor specimen. In all experiments, the same WGA
protocol was used for both test and reference samples. A
summary of the correlation data from replicate experiments is
given in Table 3.
GenomePlex gave highly representative data compared
with unamplified controls from frozen material (R2 = 0.898),
which demonstrated no statistical difference from the control
experiments of unamplified frozen template DNA (R2 =
0.935, Table 2), thus being consistent with the limits of
experimental variation. DOP-PCR gave less accurate results,
resulting in a Pearson’s correlation coefficient of 0.740,
significantly lower than both unamplified controls and
GenomePlex:unamplified hybridizations ( p < 0.001, t test).
This could be seen in plots of all aCGH data in genome order
(Fig. 2A), which shows a more variable (‘‘noisy’’) pattern in
the DOP-PCR-amplified material compared with GenomePlex
and unamplified experiments. This was reflected in the mean
absolute deviations (MADs) of the log2 ratios, calculated for
all BACs across the genome (excluding X and Y) in which
entire chromosomal arms were gained, were lost, or showed
Fig. 2. aCGH of amplified and unamplified frozen and FFPE samples. (A) Genome plots of log2 ratios plotted on the y axis for each BAC clone on the array and
plotted in genome order on the x axis. Log2 ratios of +0.2 (green) and 0.2 (red) are plotted. The dashed vertical lines represent the centromeres. Left: frozen
samples. Right: FFPE samples. Unamplified, DOP-PCR, and GenomePlex experiments are shown. (B) Upper right: Correlation plots of log2 ratios for each BAC
clone between experiments, with linear regression and Pearson’s correlation coefficients given. Lower left: Bland-Altman plots of the differences between two BAC
clones measured by two experiments on the y axis against the mean log2 ratio of the two on the x axis. Standard deviation of mean differences is plotted in purple, the
mean in black.
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was 0.049, compared with 0.0583 for GenomePlex and 0.102
for DOP-PCR.
In FFPE tissue, the effects of DOP-PCR amplification were
even more pronounced. The correlation coefficient for FFPE
DOP-PCR compared with FFPE unamplified was 0.516, which
was significantly lower than unamplified FFPE:unamplified
FFPE control experiments (0.887, p < 0.001). This is in
contrast to GenomePlex, which from FFPE showed a
correlation with unamplified DNA of 0.883, representing no
significant difference from control FFPE self:self experiments(R2 = 0.887). This is also demonstrated by the genome plots of
aCGH data (Fig. 2A) and the relative MADs for FFPE template
(0.073 for unamplified, 0.081 for GenomePlex, and 0.143 for
DOP-PCR). It is worth noting the difference in results from
unamplified control experiments using frozen and FFPE
starting material (R2 = 0.842), which may reflect an inherent
drop in reliability between data from the two templates (as
observed by the differences in the MAD, of 0.049 and 0.073,
respectively), but may also reflect, in some cases, tumor
heterogeneity and sampling differences between the surgical
resection specimens.
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plots, which are shown in Fig. 2B. The lower left represents
the differences in the log2 ratios between two BAC clones
measured by two different amplification strategies in the same
tumor ( y axis) against the mean log2 ratio of the two (x axis).
This allows for investigations into the bias (i.e., the mean
difference) and the limits within which most differences lie
(i.e., the limits of agreement). Relatively small differences
(reflected by distance between standard deviation of measure-
ments plotted in purple) and little bias (represented by a
‘‘flat’’ profile) are observed between GenomePlex and
unamplified samples, for both frozen and FFPE experiments.
Large differences are observed between DOP-PCR and
unamplified experiments. This is also reflected by the
correlation plots in the upper right. Some degree of ratio-
dependent biases can also be delineated between frozen and
FFPE samples, although these are less apparent in the
GenomePlex samples.
The degree of artifactual amplification generated by the
WGA protocols was also investigated by chromosomal
location. Certain loci previously reported to be preferentially
amplified by DOP-PCR, such as chromosomes 1p, 16p, and
19, were found to be significantly less reflective of the
unamplified data by DOP-PCR from FFPE (R2 = 0.494,
0.461, and 0.568, respectively) than with GenomePlex (R2 =
0.849, 0.838, and 0.775), which appeared to show no
significant chromosomal biases. Plots showing correlations
and log2 ratio differences between aCGH experiments are
shown for chromosomes 1 (Fig. 3A) and 16 (Fig. 3B).
Interestingly, these loci were not the least representative
regions amplified by DOP-PCR in our experiments with FFPE,
as chromosomes 3 (R2 = 0.373, Fig. 3C) and 13q (R2 = 0.326,
Fig. 3D) performed even more poorly.
Starting concentration of template DNA
Finally we investigated the effects of different starting
amounts of FFPE template DNA on the efficacy of
GenomePlex amplification. Fig. 4A shows the average
correlation and Bland-Altman plots for replicate experiments
using starting concentrations of 5, 10, and 50 ng of FFPE
DNA. The Pearson’s correlation coefficients are highly
representative of the unamplified data for all amplifications,
with 5 ng template FFPE DNA giving the best results (R2 =
0.918). Correlations between all amplifications are excellent
and reflect no difference between the measured experimental
variation in our hands for this technique. No systematic
biases are seen with different amounts of template DNA
concentration. The genome plots derived from as little as 5
ng of FFPE DNA are essentially identical to those from
unamplified material (Fig. 4B). The MADs for these
experiments showed no statistical differences (0.073 for
unamplified, 0.078 for 50 ng, 0.077 for 10 ng, and 0.069
for 5 ng). There were no biases observed at different genomic
locations and no significant differences in Pearson’s correla-
tion coefficients between different chromosomal arms (data
not shown).Discussion
We have successfully applied a novel method of WGA, the
GenomePlex technique of amplifying universal adaptor-linked
DNA fragments, to produce reproducible and accurate aCGH
profiles of FFPE tumor samples using as little as 5 ng starting
DNA. Array CGH using these samples allowed the determi-
nation of copy number gains and losses by hybridization to
BAC clones with a 0.9-Mb resolution throughout the genome,
with no chromosomal bias and with identical qualitative results
compared with unamplified samples.
We compared the GenomePlex system with DOP-PCR, a
mainstay of WGA and the application of metaphase chromo-
somal CGH to FFPE tissues. Although there are reports of
amplification and/or hybridization biases using DOP-PCR for
chromosomal CGH, the technique has successfully been
applied to a large range of samples with good results, provided
care is taken with experimental design and interpretation [4–
7,14,15]. Using the higher spatial resolution of aCGH to BAC
clones, we report here the relatively poor results obtained with
DOP-PCR amplified products, particularly using FFPE starting
material. Although DOP amplification yielded more product
than GenomePlex from a wider variety of samples, this did not
produce better quality aCGH, with Pearson’s correlation
coefficients significantly reduced across the genome. This
was despite ensuring that the reference DNA was also
amplified by DOP-PCR, which has been reported to render
amplification biases inconspicuous even at the higher sensitiv-
ity of aCGH [16–18], although these experiments were carried
out on low-resolution microarray platforms. The sources of
these biases are not well understood, but have been suggested
to reflect differential hybridization of test versus reference
samples to GC-rich regions of the genome, which is
exaggerated after biased amplification of these regions [19].
Interestingly the previously described problem loci including
chromosomes 1p, 16p, and 19 were not the least reliable in our
system, with regions on chromosomes 3 and 13q giving even
more pronounced differences in aCGH profiles.
GenomePlex WGA begins with the random, nonenzymatic
fragmentation of the genome followed by the conversion of
these fragments into PCR-amplifiable units flanked by univer-
sal adaptor sequences. This library of fragments is then
subjected to a limited number of PCR cycles to generate
sufficient material for subsequent use in a variety of
downstream applications. The requirement of fragmented
DNA makes this technique ideal for use with FFPE samples,
as the formalin fixation routinely used in histopathology
laboratories for optimum preservation of tissue morphology
is known to cross-link and fragment the genomic DNA.
GenomePlex-derived aCGH profiles from FFPE have been
demonstrated to be highly reflective of the unamplified
situation, with Pearson’s correlation coefficients essentially
identical to control self:self hybridization, demonstrating the
reproducibility in the range of normal experimental error. With
as little as 5 ng starting material, equivalent to small foci of
laser microdissected lesions, accurate assessment of DNA copy
number gains and losses was reliably achieved.
Fig. 3. aCGH of (A) chromosomes 1, (B) 16, (C) 3, and (D) 13 from amplified and unamplified frozen and FFPE samples. Upper right: correlation plots of log2 ratios for
each BAC clone between experiments, with linear regression and Pearson’s correlation coefficients given. Lower left: differences in log2 ratios between experiments
plotted on the y axis for each clone in genomic location along the chromosome on the x axis. Log2 ratios of +0.2 (green) and0.2 (red) are plotted. The dashed vertical
lines represent the centromeres.
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bacteriophage Phi29 DNA polymerase random-primed ampli-
fication based on an isothermal strand displacement reaction
[20,21]. This technique utilizes random hexamer primers to
anneal to the genomic template at multiple sites, with Phi29
polymerase initiating replication at these sites on denatured
linear DNA. As synthesis proceeds, strand displacement of
complementary DNA generates new single-stranded DNA
available to be primed by additional primers. The absoluterequirement of full-length genomic template appears to preclude
this method from use with FFPE samples, although reports
describing the success of CGH experiments have been published
[22]. This is surprising, given the fragmented nature of the
template FFPEDNA, as the reported data demonstrate amplified
product tens of kilobases in length. In our hands, any product
observed with Phi29-amplified FFPE specimens has proved to
be nonspecific in our aCGH experiments (data not shown).
Other reports demonstrating the use of novel techniques such as
Fig. 4. aCGH of GenomePlex-amplified samples from different input amounts of
FFPE DNA. (A) Upper right: correlation plots of log2 ratios for each BAC clone
between experiments, with linear regression and Pearson’s correlation coeffi-
cients marked. Lower left: Bland-Altman plots of the differences between two
BAC clones measured by two experiments on the y axis against the mean log2
ratio of the two on the x axis. Standard deviation of mean differences is plotted in
purple, themean in black. (B) Genome plots of log2 ratios plotted on the y axis for
each BAC clone on the array, plotted in genome order on the x axis. Log2 ratios of
+0.2 (green) and 0.2 (red) are plotted. The dashed vertical lines represent the
centromeres. Top: unamplified FFPE DNA. Bottom: 5 ng FFPE input DNA,
GenomePlex amplified.
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material [19] are deserving of further evaluation alongside
techniques such as GenomePlex WGA.
The disadvantages of the GenomePlexWGAmethod include
the necessity for a fully optimized DNA extraction, quantita-
tion, and purification protocol. The methods presented here
worked well for approximately 58% of FFPE samples tested,
which is a far lower success rate of amplification than DOP-
PCR. This is presumably at least in part due to inhibitors in the
extraction procedure interfering with components of the
commercial GenomePlex kit. Factors including different fixa-
tion and processing protocols between different histopathology
departments mean that the success rate may vary considerably
between samples obtained from different centers. Our own
experience suggests that this is more pronounced for Genome-Plex than for other WGA techniques, including DOP-PCR.
Such problems must be taken into consideration when planning
a study based on WGA amplification of FFPE samples, as
should be the financial implications of a commercial kit with
potentially limited success rate in any given cohort.
In summary, we show that GenomePlex WGA represents a
highly accurate and efficient method to amplify DNA samples
from FFPE material. This WGA method should readily lend
itself to the determination of DNA copy number alterations and
other high-resolution molecular genetics analyses to a range of
human diseases. However, care must be taken to optimize the
DNA extraction procedure and to evaluate success rates in
individual sample collections.
Materials and methods
Samples and DNA extraction
Wilms tumor samples were obtained from the Royal Marsden Hospital with
full local ethics committee approval. Cases were selected where possible to have
matching fresh-frozen and formalin-fixed paraffin-embedded material available.
A total of 40 samples were subjected to DNA extraction and WGA, including 5
matched frozen/FFPE pairs. FFPE samples were either cut as rolled sections (10
Am) into a 1.5-ml tube for DNA extraction or else manually or laser-assisted
microdissected (PixCell LCM system; Arcturus, Mountain View, CA, USA) and
placed in 0.5-ml tubes.Microdissected sections were stainedwith nuclear fast red
(Vector Laboratories, Burlingame, CA, USA) to aid in morphological assessment
without interfering with downstream amplification protocols, as has been
reported for hematoxylin [23].
Genomic DNA from fresh-frozen samples was extracted using a standard
proteinase K digestion followed by phenol/chloroform extraction and resus-
pended in water. FFPE material from rolled sections was extracted using the
QiaAmp DNA Mini Kit (Qiagen) according to the manufacturer’s instructions.
For microdissected FFPE samples, protocols tested included simple overnight
incubation in proteinase K (Invitrogen, Paisley, UK) at 55-C either in
manufacturer’s buffer or in buffer containing 50 mM KCl; 10 mM Tris-HCl,
pH 8.0; 2.5 mMMgCl2; 0.1 mg/ml gelatin; 0.45% NP-40; and 0.45% Tween 20
[4] and MagneSil fixed tissue genomic DNA extraction system (Promega,
Madison, WI, USA), according to the manufacturer’s instructions. The protocol
determined to give the best results for WGA by GenomePlex, and which was
used in all subsequent experiments, utilized the Qiagen DNeasy Tissue Kit
(Qiagen), with additional proteinase K digestions at 55-C overnight for up to
three subsequent rounds for smaller samples. DNA quantitation was determined
either by fluorescence (PicoGreen; Molecular Probes, Eugene, OR, USA) or
spectrophotometry (NanoDrop, Wilmington, DE, USA).
Whole genome amplification
DOP-PCR
DOP-PCR was carried out as previously described [24]. Briefly, reaction
mixtures contained 0.2 mM deoxynucleoside triphosphates (dATP, dTTP,
dCTP, dGTP), 2.0 AM DOP primer [10], 4 mM MgCl2, 2.5 U Taq polymerase
(ABGene, Epsom, UK) and different quantities of template DNA. Thermal
cycling conditions were as follows: 94-C for 9 min; 94-C for 1 min, 30-C for
1.5 min, and 72-C for 3 min (8 cycles); 94-C for 1 min, 62-C for 1 min, and
72-C for 1.5 min (25 cycles); followed by a final incubation at 72-C for 8 min.
GenomePlex
GenomePlex amplification (Rubicon Genomics/Sigma-Aldrich, Poole, UK)
was carried out according to the manufacturer’s instructions. Briefly, different
quantities of template DNA were incubated at 95-C for 4 min in 1
fragmentation buffer, and the sample was cooled on ice. The sample was further
incubated with the Library Preparation Buffer and Library Stabilization Solution
at 95-C for 2 min and the sample cooled on ice. One microliter of Library
Preparation Enzyme was added and the mix incubated at 16-C for 20 min, 24-C
S.E. Little et al. / Genomics 87 (2006) 298–306 305for 20 min, 37-C for 20 min, and 75-C for 5 min. The resulting sample was
amplified using Titanium Taq polymerase (BD Biosciences, Franklin Lakes, NJ,
USA), after initial denaturation at 95-C for 3min and for 14 cycles of 94-C for 15
s, 65-C for 5 min. Amplification products were purified using QiaQuick PCR
purification columns (Qiagen) according to the manufacturer’s instructions and
diluted with EB buffer. DNAwas quantitated either by fluorescence (PicoGreen;
Molecular Probes) or by spectrophotometry (NanoDrop).
Microarray CGH
The aCGH platform used in this study was constructed by the Breakthrough
Breast Cancer Research Centre and comprises 5623 BAC clones, spaced at
approximately 0.9 Mb throughout the genome, spotted in duplicate onto
Corning GAPSII-coated glass slides (Corning, NY, USA). In all experiments,
both ‘‘test’’ (tumor) and ‘‘reference’’ (normal female genomic DNA from
healthy volunteers) were amplified with the same WGA protocol. Hybridiza-
tions were carried out as previously described (R. Natrajan et al., submitted for
publication). Briefly, 1 Ag of test and normal female genomic DNAwas labeled
directly with Cy3-dCTP or Cy5-dCTP (Amersham BioSciences, Amersham,
UK) using a Bioprime labeling kit (Invitrogen, Paisley, UK) according to the
manufacturer’s protocol modified to incorporate 1.0 mM Cy dye, 0.6 mM
dCTP, and 1.2 mM dATP, dGTP, and dTTP. Unincorporated nucleotides were
removed with MinElute purification columns (Qiagen). The labeled DNA was
coprecipitated with 100 Ag of Cot-1 DNA (Invitrogen), resuspended in
hybridization buffer (50% formamide, 10% dextran sulfate, 2 SSC, 2%
SDS, 2 mg yeast tRNA (Invitrogen)), denatured at 75-C for 15 min, and
preannealed for 30 min at 37-C. Slides were blocked in 10% BSA/50%
formamide solution at 42-C for 45 min. The probe was subsequently applied to
the slide and hybridized overnight at 42-C. Slides were rinsed in 1 PBS to
remove coverslips; 2 SSC, 0.1% SDS with mild agitation at 70-C for 20 min;
1 PBS with mild agitation at room temperature for 20 min; and finally in
0.2 SSC followed by deionized water for 10 s. Slides were centrifuged at
1200 rpm for 2 min to dry.
Image acquisition and data analysis
Slides were scanned using an Axon 4000B scanner (Axon Instruments,
Burlingame, CA, USA) and images were analyzed using Genepix Pro 4.1
software (Axon Instruments). The median localized background slide signal for
each clone was subtracted and each clone Cy5/Cy3 ratio subjected to print-tip
loess normalization [25]. BAC clone replicate spots were averaged and clones
with poor reproducibility between replicates excluded (standard deviation
>0.2). In addition, clones with missing/poor values in >70% samples were
excluded, as were those with no mapping information (May 2004 build of the
human genome sequence, hg17). The final dataset comprised 22 hybridizations
and 5096 clones. All data transformation and statistical analyses were carried
out in R 2.0.1 (http://www.r-project.org/) and BioConductor 1.5 (http://
www.bioconductor.org/), making extensive use of modified versions of the
package aCGH in particular [26]. Correlations were calculated using Pearson
coefficients. Investigations into systematic bias were made using Bland-Altman
plots [27,28]. Differences in clone measurements by different techniques were
also plotted separated by chromosome according to their genomic location.
MADs of the log2 ratios were calculated for all BACs across the genome
(excluding those on chromosomes X and Y) in which entire chromosomal arms
were gained, were lost, or showed no change.
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